Johnson & Johnson Company Analysis - Research and Markets

The publisher explores Johnson & Johnson’s prescription pharmaceutical performance and outlook over 2019–29.

Snapshot

Overview: Johnson & Johnson’s growth will be driven by its pharmaceuticals segment.
Key themes: [1] Oncology will be a considerable growth driver for Johnson & Johnson, as Darzalex and Imbruvica exhibit robust growth at blockbuster levels [2] Growth from immunology products Stelara and Tremfya will counter increasing biosimilar headwinds to Remicade [3] Johnson & Johnson’s neuroscience portfolio will also drive growth, with the Invega franchise and recently launched Spravato, along with key pipeline asset ponesimod.

Model updates (30 July 2020)

Darzalex forecast adjusted higher due to continued strong growth and market share gains, driven by patient uptake across all lines of therapy.
Tremfya sales adjusted lower due to current sales trends.

Model updates (1 June 2020)

Model updates (26 February 2020)

Remicade forecast adjusted lower due to additional biosimilar launches in the US and increased discounts and rebates
Simponi forecast adjusted lower in Rest of World due to competition
Stelara forecast adjusted higher due to strong uptake in Crohn’s disease
Tremfya forecast adjusted higher due to uptake in psoriasis
Prezista / Prezcobix / Rezolsta / Symtuza forecast adjusted higher due to consolidation of JNJ’s HIV portfolio under one product entry, bringing in line with how JNJ reports
Symtuza forecast removed due to above-mentioned consolidation
Invega Sustenna / Trinza forecast adjusted higher due to new patient starts and persistency
Darzalex forecast adjusted higher due to continued strong market growth and share gains in the US and Europe, driven by patient uptake in all lines of therapy
Imbruvica forecast adjusted higher due to increased patient uptake globally and higher market share, driven primarily by first-line chronic lymphocytic leukemia
Zytiga forecast adjusted higher due to stronger-than-expected performance of authorized generic in the US and strong sales and share growth in Europe
Velcade forecast adjusted lower due to generic competition
Xarelto forecast adjusted higher in the US due to volume and market growth
Invokana forecast adjusted lower due to market share losses and safety label update
JNJ-4528 forecast pulled forward due to earlier-than-expected US and European filings, and a Chinese approval decision expected in late 2020.

Model updates (15 October 2019)

Remicade sales adjusted higher internationally due to better-than-anticipated performance
Stelara sales adjusted higher due to continued share gains in Crohn’s disease
Tremfya sales adjusted higher due to strong uptake in psoriasis
Imbruvica sales adjusted higher due to increased patient uptake globally, higher market share, and growth across multiple indications, primarily in first-line chronic lymphocytic leukemia
Velcade sales adjusted lower due to higher initial impact of generic competition
Xarelto sales adjusted higher due to better-than-expected volume growth offsetting the increased reimbursement issues seen in the US
Tracleer sales adjusted lower due to higher impact of generics.

Model updates (18 July 2019)

Darzalex sales adjusted higher due to continued penetration and market share gains
Xarelto sales adjusted lower due to significant reimbursement issues in the US, notably the increase in the legislative rate for the donut hole from 50% to 70%, along with higher Medicare and donut hole utilization
Zytiga sales adjusted higher due to lower-than-anticipated generic impact in the US and recent approvals in Europe and Asia for metastatic high-risk castration-sensitive prostate cancer based on the Phase III LATITUDE study
Balversa forecast added
JNJ-4528 (BCMA CAR-T) forecast added
Ponesimod forecast added.

Company Background

Recent Earnings Review

Company Forecast

Company Profile

Clinical Trial Overview

Table of Contents